Summary
The results of the European Working Party for Hypertension in the Elderly Study showed that treatment of high blood pressure reduced the morbidity and mortality from strokes and myocardial infarction and reduced the incidence of heart failure in elderly patients. The largest number of hypertensive patients are elderly, and it is in this group of patients that the maximum benefit of treatment might be expected. The present study was designed to study in detail the efficacy and tolerability of ketanserin in an elderly population. Seventeen elderly (> 70 years) patients with a lying systolic blood pressure of 160 mmHg and/or a diastolic blood pressure of ≥ 90 mmHg were included in the study. For the 12 patients who completed the study, the mean blood pressure was significantly reduced on ketanserin compared with placebo (p<0.001) in the supine and erect positions. The mean net changes in blood pressure after 8 weeks were 21/17 mmHg and 23/16 mmHg erect. Heart rate was also significantly reduced (p<0.001) by a mean of 8 beats/min lying and 9 beats/min erect. Analysis of ambulatory 24-hour ECG tapes showed no significant effect of ketanserin on heart rhythms. Ketanserin therapy had no significant effect on routine hematology, plasma electrolytes, biochemistry, or urinalysis. Total exchangeable sodium and potassium and body weight were also unchanged. On ketanserin treatment, the overall quality of life score was significantly improved (p=0.002; analysis of variance on log transformed data) compared with the placebo phase.
Similar content being viewed by others
References
European Working Party on High Blood Pressure in the Elderly. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1:1349–1354.
Tuck ML. Clinical care of the ageing hypertensive patient. J Cardiovasc Pharmacol 1988;12(Suppl 8):S40-S48.
Vanhoutte P, Amery A, Birkenhager W, et al. Serotonergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension 1988;11(2):111–133.
Rossendorff C, Murray GD. Ketanserin versus metoprolol and hydrochlorothiazide in essential hypertension: Only ketanserin's hypotensive effect is age related. J Hypertens 1986;4(Suppl 6):S109-S111.
In-house data: Janssen Pharmaceutical Ltd., Grove, Wantage, Oxon, OX12 ODQ, UK.
Turner JF, Gould SE, Wellburn PJ et al. The effect of antihypertensive treatment on the assessment of wellbeing in a general practice population. J Hypertens 1987;5(Suppl 5):S529-S531.
McGourty JC, Silas JH, Cowen KJ. Controlled trial of ketanserin in hypertension. Br J Clin Pharmacol 1985;20:37–40.
Cameron HA, Ramsay LE. Ketanserin in essential hypertension: A double blind placebo controlled study. Postgrad Med J 1985;61:583–586.
Zehender M, Meinvertz T, Hohntoser S. Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Am J Cardiol 1989:P826–P832.
Marks C, Dews I, Gould S, et al. The effects of ketanserin on ventricular ectopic activity in man. Cardiovasc Drugs Ther, this issue.
The PACK Trial Group. Randomized trial of ketanserin for prevention of atherosclerotic complications. Br Med J 1989;298:424–430.
Turner JF, Gould SE, Welburn PJ, et al. The effect of antihypertensive treatment on the assessment of well-being in a general practice population. J Hypertens 1987;5(Suppl 5):S529-S531.
Korlipara K, Gould SE, Taylor NA, et al. Comparative trial of ketanserin or bendrofluazide as add-on therapy in hypertensive patients uncontrolled on a β-blocker alone. Drugs 1988;36(Suppl 1):130–134.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McCarthy, S.T., McCarthy, G.L., John, S.M. et al. A placebo-controlled crossover study of ketanserin in elderly hypertensive patients. Cardiovasc Drug Ther 4, 115–117 (1990). https://doi.org/10.1007/BF00053441
Issue Date:
DOI: https://doi.org/10.1007/BF00053441